December 9, 2022
RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
National Heart, Lung, and Blood Institute (NHLBI)
The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) will hold a pre-application technical assistance webinar regarding applications for the following RFAs:
RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
This pre-application webinar will take place on January 25, 2023 at 2:00 PM EST. The purpose of and requirements for both RFAs will be reviewed. Attendees will have the opportunity to ask questions. Program staff from the NHLBI and the National Center for Advancing Translational Sciences (NCATS) will be available to provide responses.
While not required, participation in the webinar is strongly encouraged. Potential applicants are strongly encouraged to submit questions prior to the webinars to [email protected]. Please indicate "Phase IIB Program Webinar" in the subject line of the email.
To register for the webinar, please visit https://nih.zoomgov.com/webinar/register/WN_IJ1qfVjJTHaVtv3jAoaweg.
Stephanie Davis, Ph.D.
Innovation and Commercialization Office
Division of Extramural Research Activities
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-496-8412
Email: [email protected]
and Human Services (HHS)
